German Hodgkin Study Group (GHSG), Gerhart-Hauptmann-Str. 18, 59555 Lippstadt, Germany.
Expert Rev Hematol. 2010 Oct;3(5):583-92. doi: 10.1586/ehm.10.50.
Depending on stage and risk factor profile, up to 95% of patients with Hodgkin lymphoma at first presentation reach complete remission after the initial standard treatment including radiotherapy, combination chemotherapy or combined modality therapy. Patients who relapse after first complete remission can achieve a second complete remission and long-term disease-free survival with salvage treatment including radiotherapy for localized relapse in previously nonirradiated areas, conventional salvage chemotherapy, or high-dose chemotherapy with stem cell transplantation. In general, risk-adapted treatment strategies are used in the treatment of patients with Hodgkin lymphoma. Adequate staging of newly diagnosed patients enables optimal treatment planning, which is of particular importance for finding a balance between treatment efficacy and toxicity. In this review, an overview is given of the current knowledge of clinical and biological risk factors and the role of imaging modalities during and after treatment.
根据分期和危险因素情况,多达 95%的初诊霍奇金淋巴瘤患者在初始标准治疗(包括放疗、联合化疗或联合治疗)后达到完全缓解。首次完全缓解后复发的患者可以通过挽救治疗实现第二次完全缓解和长期无病生存,挽救治疗包括对以前未照射区域进行局部复发的放疗、常规挽救化疗或大剂量化疗联合干细胞移植。一般来说,霍奇金淋巴瘤患者的治疗采用风险适应策略。对新诊断患者进行充分分期可实现最佳治疗计划,这对于在治疗效果和毒性之间找到平衡尤为重要。在这篇综述中,概述了临床和生物学危险因素以及治疗期间和治疗后的影像学方式的作用的现有知识。